Zacks.com on MSN1h
Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics
The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast ...
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
news.crunchbase3h
Funding Is Flush For Startups Focused On Treating Pain
As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in ...
BioPharma Dive10h
Merck shares tumble as company pauses Gardasil shipments to China
Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.
Why Trump’s threatened pharmaceutical tariffs would be unlikely to lower prices in the U.S.
U.S. President Donald Trump has repeatedly mentioned pharmaceuticals as another industry that could be targeted by tariffs, ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.53% to $482.28 Tuesday, on what proved to be an all-around great trading ...
Times News19h
FDA approves painkiller designed to eliminate risk of addiction
Federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S.